Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 5Recruiting 3Completed 3Unknown 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Plasmablastic Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Rituximab 55Cyclophosphamide 38Vincristine 25Prednisone 24Doxorubicin 21Cytarabine 18Etoposide 17Lenalidomide 16Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7zanubrutinib 6R-CHOP protocol 6Vindesine 5Radiotherapy 5Dexamethasone 5Busulfan 5ibrutinib 4fludarabine phosphate 4Methylprednisolone 4Epirubicin 4Decitabine 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × prednylidene × Clear all
NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡